Increased frequency and suppressive activity of CD127low/− regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement
暂无分享,去创建一个
[1] P. Krammer,et al. Molecular Mechanisms of Treg-Mediated T Cell Suppression , 2012, Front. Immun..
[2] Yi-xiang Han,et al. Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia , 2011, International journal of cancer.
[3] D. Long,et al. Increased Frequency of CD4+CD25highFoxP3+ Regulatory T Cells in Patients with Hepatocellular Carcinoma , 2011, Archivum Immunologiae et Therapiae Experimentalis.
[4] M. Carini,et al. Frequency of regulatory T cells in peripheral blood and in tumour‐infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma , 2011, BJU international.
[5] P. Delvenne,et al. Immune Suppression in Head and Neck Cancers: A Review , 2011, Clinical & developmental immunology.
[6] S. Lang,et al. Toll-like Receptors in Regulatory T Cells of Patients With Head and Neck Cancer. , 2010, Archives of otolaryngology--head & neck surgery.
[7] G. Li,et al. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma , 2010, Clinical and experimental immunology.
[8] J. Greenman,et al. Serum IL10 and circulating CD4+CD25high regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma , 2010, Head & neck.
[9] B. Wollenberg,et al. Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. , 2010, International journal of molecular medicine.
[10] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[11] G. Garlet,et al. Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment , 2010, Cancer Immunology, Immunotherapy.
[12] Ti Zhang,et al. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma , 2010, Journal of Cancer Research and Clinical Oncology.
[13] T. Whiteside,et al. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. , 2009, Journal of immunological methods.
[14] E. Shevach. Mechanisms of foxp3+ T regulatory cell-mediated suppression. , 2009, Immunity.
[15] M. Hashibe,et al. Recent changes in the epidemiology of head and neck cancer , 2009, Current opinion in oncology.
[16] Dakang Xu,et al. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. , 2009, Clinical immunology.
[17] M. Chovanec,et al. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck , 2009, Journal of cellular and molecular medicine.
[18] H. Fujii,et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer , 2008, International journal of cancer.
[19] J. Schlom,et al. Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer , 2008, Clinical Cancer Research.
[20] T. Whiteside,et al. The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.
[21] T. Whiteside,et al. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck , 2007, Head & neck.
[22] J. McCune,et al. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. , 2007, Journal of immunological methods.
[23] J. Woo,et al. Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patients , 2007, British Journal of Cancer.
[24] W. Selby,et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.
[25] T. Gingeras,et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.
[26] S. Kim-Schulze,et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[28] T. Whiteside,et al. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer , 2005, British Journal of Cancer.
[29] S. Sakaguchi,et al. CD4+ Tregs and immune control. , 2004, The Journal of clinical investigation.
[30] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[31] T. Whiteside,et al. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] T. Whiteside,et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] G. Freeman,et al. CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.
[34] M. Roncarolo,et al. Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.
[35] D. Sidransky,et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.
[36] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.
[37] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[38] T. Ye,et al. Expression of CD4+CD25highCD127low/− regulatory T cells in transitional cell carcinoma patients and its significance , 2009, Journal of clinical laboratory analysis.
[39] J. Schlom,et al. Enhanced Functionality of CD 4 + CD 25 highFoxP 3 + RegulatoryTCells in the Peripheral Blood of Patients with Prostate Cancer , 2008 .
[40] 水上 佳樹. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3[+] regulatory T cells in gastric cancer , 2008 .
[41] Maura L Gillison,et al. BASIC SCIENCE REVIEW , 2006 .
[42] Ray H. Baughman,et al. Supporting Online Material , 2003 .
[43] G. Freeman,et al. CD4CD25 Regulatory Cells in Human Peripheral Blood , 2001 .